VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BigKNY3 who wrote (2583)	11/18/1997 12:17:00 PM
From: Gene Voss	of 23519

Easy,with a relatively young healthy group of men I would expect a low degree of side affects.I can assure you no high risk patints were included.When released to the general population any agent capable of affecting multiple organ systems will have serious potential side affects. For priapism to occure you need a potent agent which will over ride the bodies ability to detumesce the penis.As I've said before I believe this to be a relatively weak agent,proof of which is no prolonged erections. I'm sure the reported safety and efficacy are easily explained ,look at the population studied.When the specifics of the data are released we'll see a relatively young group with no proven,substantiated erectile dysfunction,which explains the efficacy and safety. Your statement regarding the positive review by a respected analyst is curious.He can only evaluate data he's given by Pfizer.He would have to be an extremely astute analyst to appreciate the complexity of this issue and the dynamics of the problem to identify a flaw in the trials.Especially since I doubt he would have access to data the specialists in this area haven't seen. GV

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next